Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-02-2009 | Original Article

Reduced striatal D₂ receptor binding in myoclonus–dystonia

Authors: R. J. Beukers, J. Booij, N. Weisscher, F. Zijlstra, T. A. M. J. van Amelsvoort, M. A. J. Tijssen

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2009

Abstract

Purpose

To study striatal dopamine D₂ receptor availability in DYT11 mutation carriers of the autosomal dominantly inherited disorder myoclonus–dystonia (M–D).

Methods

Fifteen DYT11 mutation carriers (11 clinically affected) and 15 age- and sex-matched controls were studied using ¹²³I-IBZM SPECT. Specific striatal binding ratios were calculated using standard templates for striatum and occipital areas.

Results

Multivariate analysis with corrections for ageing and smoking showed significantly lower specific striatal to occipital IBZM uptake ratios (SORs) both in the left and right striatum in clinically affected patients and also in all DYT11 mutation carriers compared to control subjects.

Conclusions

Our findings are consistent with the theory of reduced dopamine D₂ receptor (D2R) availability in dystonia, although the possibility of increased endogenous dopamine, and consequently, competitive D2R occupancy cannot be ruled out.

Zimprich A, Grabowski M, Asmus F, et al. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus–dystonia syndrome. Nat Genet 2001;29:66–9.PubMedCrossRef

Klein C. Myoclonus and myoclonus–dystonias. In: Pulst SM, editor. Genetics of movement disorders. Boston: Academic; 2003. p. 449–69.

Asmus F, Gasser T. Inherited myoclonus–dystonia. Adv Neurol 2004;94:113–9.PubMed

Piras G El Kharroubi A, Kozlov S, et al. Zac1 (Lot1), a potential tumor suppressor gene, and the gene for epsilon-sarcoglycan are maternally imprinted genes: identification by a subtractive screen of novel uniparental fibroblast lines. Mol Cell Biol 2000;20:3308–15.CrossRef

Gerrits MC, Foncke EM, de Haan R, et al. Phenotype–genotype correlation in Dutch patients with myoclonus–dystonia. Neurology 2006;66:759–61.PubMedCrossRef

Grimes DA, Han F, Lang AE, St George-Hyssop P, Rachaco L Bulman DE. A novel locus for inherited myoclonus dystonia on 18p11. Neurology 2002;59:1183–6.PubMed

Schule B, Kock N, Svetel M, et al. Genetic heterogeneity in ten families with myoclonus–dystonia. J Neurol Neurosurg Psychiatry 2004;75:1181–5.PubMedCrossRef

Marsden CD, Obeso JA, Zarranz JJ, Lang AE. The anatomical basis of symptomatic hemidystonia. Brain 1985;108:463–83.PubMedCrossRef

Obeso JA, Gimenez-Roldan S. Clinicopathological correlation in symptomatic dystonia. Adv Neurol 1988;50:113–22.PubMed

10.

Vitek JL. Pathophysiology of dystonia: a neuronal model. Mov Disord 2002;17(Suppl 3):S49–62.PubMedCrossRef

11.

Yokoi F, Dang MT, Li J, Li Y. Myoclonus, motor deficits, alterations in emotional responses and monoamine metabolism in epsilon sarcoglycan deficient mice. J Biochem 2006;140:141–6.PubMedCrossRef

12.

Breakefield XO, Blood AJ, Yuqing L, et al. The pathophysiological basis of dystonias. Nat Rev Neurosci 2008;9:222–34.PubMedCrossRef

13.

Esapa CT, Waite A, Locke M, et al. SGCE missense mutations that cause myoclonus–dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA. Hum Mol Genet 2007;16:327–42.PubMedCrossRef

14.

Naumann M, Pirker W, Reiners K, Lange KW, Becker G, Brucke T. Imaging the pre- and postsynaptic side of striatal dopaminergic synapses in idiopathic cervical dystonia: a SPECT study using [¹²³I]epidepride and [¹²³I]β-CIT. Mov Disord 1998;13:319–23.PubMedCrossRef

15.

Asanuma K, Ma Y, Okulski J, et al. Decreased striatal D₂ receptor binding in non-manifesting carriers of the DYT1 dystonia mutation. Neurology 2005;64:347–9.PubMed

16.

Rinne JO, Iivanainen M, Metsähonkala L, et al. Striatal dopaminergic system in dopa-responsive dystonia: a multi-tracer PET study shows increased D₂ receptors. J Neural Transm 2004;111:59–67.PubMedCrossRef

17.

Staedt J, Stoppe G, Kogler A, et al. Nocturnal myoclonus syndrome (periodic limb movements in sleep) related to central dopamine D2-receptor alteration. Eur Arch Psychiatry Clin Neurosci 1995;245:8–10.PubMedCrossRef

18.

Laruelle M, Abi-Dargham A, van Dyck CH, et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 1995;36:1182–90.PubMed

19.

Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 1985;35:73–7.PubMedCrossRef

20.

Frucht SJ, Leurgans SE, Hallett M, Fahn S. The unified myoclonus rating scale. Adv Neurol 2002;89:361–37.PubMed

21.

Costa DC, Verhoeff NP, Cullum ID, et al. In vivo characterisation of 3-iodo-6-methoxybenzamide 123I in humans. Eur J Nucl Med 1990;16:813–6.PubMedCrossRef

22.

Booij J, Korn P, Linszen DH, van Royen EA. Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med 1997;24:674–7.PubMed

23.

Booij J, Tissingh G, Boer GJ, et al. [¹²³I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997;62:133–40.PubMedCrossRef

24.

Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007;27:1533–9.PubMedCrossRef

25.

Booij J, Habraken JB, Bergmans P, et al. Imaging of dopamine transporters with iodine- 123-FP-CIT SPECT in healthy controls and patients with Parkinson’s disease. J Nucl Med 1998;39:1879–84.PubMed

26.

Grabowski M, Zimprich A, Lorenz-Depiereux B, et al. The epsilon-sarcoglycan gene (SGCE), mutated in myoclonus–dystonia syndrome, is maternally imprinted. Eur J Hum Genet 2003;11:138–44.PubMedCrossRef

27.

Foncke EMJ, Gerrits MCF, van Ruissen F, et al. Distal myoclonus and late onset in a large Dutch family with myoclonus–dystonia. Neurology 2006;67:1677–80.PubMedCrossRef

28.

Asmus F, Zimprich A, Tezenas du Montcel S, et al. Myoclonus–dystonia syndrome: epsilon-sarcoglycan mutations and phenotype. Ann Neurol 2002;52:489–92.PubMedCrossRef

29.

Beukers RJ, Foncke EMJ, van der Meer J, et al. Functional magnetic resonance imaging in myoclonus dystonia. Abstract in New Developments in Functional Research for Movement Disorders: Relevance for Clinical Practice. Amsterdam; 2006. p. 27.

30.

Parsey RV, Oquendo MA, Zae Ponce Y, et al. Dopamine D₂ receptor availability and amphetamine induced dopamine release in unipolar depression. Biol Psychiatry 2001;50:313–22.PubMedCrossRef

31.

Meyer JH, McNeely HE, Sagrati S, et al. Elevated putamen D₂ receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Am J Psychiatry 2006;163:1594–602.PubMedCrossRef

32.

Schneier FR, Liebowitz MR, Abi-Dargham A, Lin SA, Laruelle M. Low dopamine D₂ receptor binding potential in social phobia. Am J Psychiatry 2000;157:457–9.PubMedCrossRef

33.

Yang YK, Yao WJ, McEvoy JP, et al. Striatal dopamine D2/D3 receptor availability in male smokers. Psychiatry Res 2006;146:87–90.PubMedCrossRef

34.

Scott DJ, Domino EF, Heitzeg MM, et al. Smoking modulation of μ-opioid and dopamine D₂ receptor-mediated neurotransmission in humans. Neuropsychopharmacology 2007;32:450–7.PubMedCrossRef

35.

Volkow ND, Wang GJ, Begleiter H, et al. High levels of dopamine D₂ receptors in unaffected members of alcoholic families: possible protective factors. Arch Gen Psychiatry 2006;63:999–1008.PubMedCrossRef

36.

Fehr C, Yakushev I, Hohmann N, et al. Association of low striatal dopamine D₂ receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am J Psychiatry 2008;165(4):507–14.PubMedCrossRef

37.

Ichise M, Ballinger JR, Tanaka F, et al. Age-related changes in D₂ receptor binding with iodine-123-iodobenzofuran SPECT. J Nucl Med 1998;39:1511–8.PubMed

38.

Larisch R, Meyer W, Klimke A, et al. Left–right asymmetry of striatal dopamine D₂ receptors. Nucl Med Commun 1998;19:781–7.PubMed

39.

Grünewald A, Djarmati A, Lohmann-Hedrich K, et al. Myoclonus–dystonia: significance of large SGCE deletions. Hum Mutat 2008;29:331–2.PubMedCrossRef

Title: Reduced striatal D2 receptor binding in myoclonus–dystonia
Authors: R. J. Beukers
J. Booij
N. Weisscher
F. Zijlstra
T. A. M. J. van Amelsvoort
M. A. J. Tijssen
Publication date: 01-02-2009
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0924-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Reduced striatal D₂ receptor binding in myoclonus–dystonia

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2009

Technetium-99m pyrophosphate/thallium-201 dual-isotope SPECT imaging predicts reperfusion injury in patients with acute myocardial infarction after reperfusion

Correlation of apparent diffusion coefficients measured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer

FDG PET/CT findings in secondary hyperparathyroidism not mimicking multiple bone metastases

Multimodality molecular imaging — from target description to clinical studies

Correlation of [18F]FMISO autoradiography and pimonidazole immunohistochemistry in human head and neck carcinoma xenografts

[18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model